U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT07456371) titled 'PIC1 Injection Therapy for Relapsed/Refractory B-NHL' on March 02.
Brief Summary: This is an investigator-initiated trial aimed at assessing the safety and efficacy of PIC1 injection in the treatment of relapsed/refractory B-cell Non-Hodgkin Lymphoma.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Non-Hodgkin Lymphoma
Intervention:
BIOLOGICAL: PIC1 Injection
Three dose groups (1.0x10^9 TU, 2.0x10^9 TU, 4.0x10^9 TU) were set up, starting from the low dose group climbing to explore the safe and effective dose.
Recruitment Status: RECRUITING
Sponsor: Chongqing Precision Biotech Co., Ltd
Disclaimer: Curate...